Drug Profile
Research programme: anti-obesity monolconal antibodies - Lanier Biotherapeutics
Alternative Names: 10F 7; 2C 6; Anti-hPVA mAbs; Anti-PCSK9 mAbs; Pre-adipocytes monoclonal antibodiesLatest Information Update: 07 Oct 2021
Price :
$50
*
At a glance
- Originator Abeome Corporation
- Developer Lanier Biotherapeutics
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators; PCSK9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Diabetes mellitus; Hypercholesterolaemia; Obesity
Most Recent Events
- 05 Oct 2021 Biophtha has merged with Abeome Corporation to form Lanier Biotherapeutics
- 28 May 2021 No recent reports of development identified for preclinical development in Obesity in USA (Injection)
- 28 May 2021 No recent reports of development identified for research development in Diabetes-mellitus in USA (Parenteral)